lab representative inspecting a vile


Robert Moscato


Mr. Moscato is a serial pharmaceutical entrepreneur who has amassed his knowledge during more than 20 years in the pharmaceutical industry, including c-suite leadership and commercial roles. He has successfully built companies from the ground to an integrated organization. Mr. Moscato served as the President and Chief Operating Officer of Cerecor, Inc. (NASDAQ: CERC) from November 2017 until March 2018, and he served on the Board of Directors of Cerecor Inc. from November 2017 until May 2018. Mr. Moscato co-founded Zylera Pharmaceuticals, LLC and served as the CEO for over six years until it was acquired by Cerecor, Inc. in November 2017. Prior to that, Mr. Moscato served as Chief Operating Officer of Deston Therapeutics LLC. Mr. Moscato initially built his career in commercial roles of increasing responsibility with GlaxoSmithKline, where he was a member of the brand team that led the launch of Wellbutrin XL – one of the fastest launches in pharmaceutical history. Mr. Moscato earned an A.S. degree in Food and Nutrition from SUNY Farmingdale, a B.S. in Healthcare Management from St. Francis College and an M.B.A. from Iona College.

Erik Emerson


Mr. Emerson most recently served as the President and Chief Executive Officer of Symplmed Pharmaceuticals, which he had founded in 2013.  He had led Symplmed to the submission, approval and commercial launch of PrestaliaR, and to the eventual sale of such assets to Marina Biotech in June 2017. He also spearheaded the development and launch of Symplmed’s DyrctAxess technology, a patented software designed to manage prescription fulfillment and patient monitoring.  DyrctAxess has demonstrated a significant impact on patient conversion to treatment, long-term compliance and overall patient retention.  Prior to founding Symplmed, Mr. Emerson served as the head of Commercial Development at XOMA from 2010 to 2013; and as Director of Marketing at Gilead Sciences from 2007 to 2010.  He began his career at King Pharmaceuticals in sales, sales training and marketing.  Mr. Emerson graduated from the University of Oregon with a Bachelor of Arts in Political Science with a specialization in Administration and Organization.

Amit Shah


Over 15 years of strong financial, accounting and auditing experience. Prior to joining Marina, Mr. Shah served as Senior Director of Finance – ERP, at Young’s Market Company. Prior to Young’s, he was the Vice President of Finance & Accounting, and Acting Chief Financial Officer, of Insightra Medical Inc.  Mr. Shah also previously served as VP Finance and Acting Chief Financial Officer at IgDraSol Inc., as Corporate Controller & Director of Finance at ISTA Pharmaceuticals, as Corporate Controller at Spectrum Pharmaceuticals, and Controller/Senior Manager Internal Audits at Caraco Pharmaceuticals Laboratories.  Mr. Shah received a Bachelor’s of Commerce degree from the University of Mumbai, and is an Associate Chartered Accountant from The Institute of Chartered Accountants of India. Mr. Shah is also an inactive CPA from Colorado, USA.

Peter Weinstein


Dr. Weinstein brings a diverse and comprehensive legal background developed from over two decades of legal, intellectual property and transactional experience.  Dr. Weinstein previously served as in-house Senior Counsel at Baxter Healthcare Corporation where he managed the legal, intellectual property and transactional projects for Baxter’s major hemophilia products and development programs.  Prior to his time at Baxter, Dr. Weinstein served as an attorney at Goodwin Procter, Brobeck Phleger & Harrson and Fish & Richardson where he handled litigation, patent prosecution and transactional matters.  More recently, Dr. Weinstein has been working with small businesses in the biotech and pharma field as CEO of Entralta, P.C. where he has led a team of legal and other professionals handling all aspects of Entralta’s clients legal and business affairs.  Prior to law school, Dr. Weinstein was a Research Fellow at the National Institutes of Health in Bethesda, MD and USAMRIID in Frederick, MD; as well as a Senior Scientist at ImmuCell Corporation.  Dr. Weinstein received his law degree from Boston College Law School and his Ph.D. in Biology/Immunology from the University of Pennsylvania.  Dr. Weinstein is a member of the California Bar and the is a registered Patent Attorney.


Scroll Up